Leukemia Research
Volume 24, Issue 7 , Pages 583-587 , July 2000

Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study

  • T Kühr

      Affiliations

    • Department of Internal Medicine, University Hospital, Anichstrasse 35, 6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding author. Tel./fax: +43-512-5043333
    • ,
  • W Eisterer

      Affiliations

    • Department of Internal Medicine, University Hospital, Anichstrasse 35, 6020 Innsbruck, Austria
    • ,
  • U Apfelbeck

      Affiliations

    • Department of Internal Medicine, University Hospital, Graz, Austria
    • ,
  • W Linkesch

      Affiliations

    • Department of Internal Medicine, University Hospital, Graz, Austria
    • ,
  • O Bechter

      Affiliations

    • Department of Internal Medicine, University Hospital, Anichstrasse 35, 6020 Innsbruck, Austria
    • ,
  • A Zabernigg

      Affiliations

    • Department of Internal Medicine, General Hospital, Kufstein, Austria
    • ,
  • K Geissler

      Affiliations

    • Department of Internal Medicine, University Hospital, Vienna, Austria
    • ,
  • G Barbieri

      Affiliations

    • Department of Internal Medicine, General Hospital, St. Pölten, Austria
    • ,
  • C Duba

      Affiliations

    • Department of Medical Biology and Human Genetics, University of Innsbruck, Innsbruck, Austria
    • ,
  • G Gastl

      Affiliations

    • Department of Internal Medicine, University Hospital, Anichstrasse 35, 6020 Innsbruck, Austria
    • ,
  • J Thaler

      Affiliations

    • Department of Internal Medicine, University Hospital, Anichstrasse 35, 6020 Innsbruck, Austria

Received 11 February 2000 ,Accepted 3 March 2000.

References 

  1. The German CML Study Group Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al.  Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994;84:4064–4077
  2. The Italian Cooperative Study Group on Chronic Myeloid Leukemia Tura S, Baccarani M, Zuffa E, Russo D, Fanin R, Zaccaria A, et al.  Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New. Engl. J. Med. 1994;330:820–825
  3. Allan NC, Richards SM, Shepherd PCA, on behalf of the UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response, Lancet 1995;345:1392–1397.
  4. Chronic Myeloid Leukemia Trialists’ Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials, J Clin Cancer Inst 1997;89:1616–1620.
  5. Guilhot F, Dreyfus B, Desmares MC, Giraud C, Huret X, Brizard A, et al.  Combined therapy interferon and chemotherapy in chronic myelogenous leukemia. Nouv. Rev. Fr. Hematol. 1989;31:171–173
  6. Guilhot F, Dreyfus B, Brizard A, Huret JL, Tanzer J. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha-2a and hydroxyurea with or without low dose cytosine arabinoside. Leukemia Lymph. 1991;4:49–55
  7. Silver RT, Benn P, Szatrowski TP, Verma R, Gutfriend A. Infusional cytosine arabinoside (Ara-C) and recombinant interferon-alpha (rIFN-alpha) for the treatment of chronic myeloid leukemia (CML). Proc. ASCO. 1990;9:209
  8. Kantarjian HM, Keating MJ, Esey EH, O’Brian S, Pierce S, Beran M, et al.  Treatment of advanced stages of Philadelphia chromosome-positive chronic myclogenous leukemia with interferon-alpha and low-dose cytarabine. J. Clin. Onc. 1992;10:772–778
  9. Arthur Q, Ma DDF. Combined interferon alph-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol. 1993;89(Suppl. 1):15
  10. Thaler J, Fluckinger T, Huber H, Lang A, Abbrederis C, Seewann H, et al.  Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2c and low-dose cytosine arabinoside. Leukemia Res. 1993;17:711–715
  11. Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, et al.  Interferon-alpha-2c and ld-ara-C for the treatment of patients with CML: preliminary results of the Austrian multicenter phase II study. Leukemia Res. 1997;21:75–80
  12. Kantaffian HM, O’Brian S, Smith TL, Rios MB, Cortes J, Beran M, et al.  Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogneous leukemia with daily doses of interferon alpha and low-dose cytarabine. J. Clin. Onc. 1999;17:284–292
  13. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al.  Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myeloid leukemia. New Engl. J. Med. 1997;337:223–229
  14. Tura S on behalf of the Italian Cooperative Study Group on CML (ICSG on CML). Cytarabine increases karyotypic response in alpha-IFN treated chronic myeloid leukemia patients: results of a national prospective randomized trial. Blood 1998;92 (Suppl 1):317a.
  15. Capizzi RL, White JC, Powell BL, Perrino E. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Sem. Haematol. 1991;28:54–69
  16. Saneyoshi M, Moruzund M, Kodama K, Machida K, Kuminaka A, Yoshino H. Synthetic nucleosides and nucleotides. XVI. Synthesis and biological evaluation of a series of 1-beta-d-arabinofuranosyl-cytosine-5′-alkyl or arylphosphates. Chem. Pharm. Bull. 1980;28:2915–2923
  17. Yoshida Y, Aymada Y, Watanabe T, Suga T, Takayama H. Participation of the peroxisomal beta-oxidation system in the cahin shortening of PCA 16, a metabolite of the cytosine arabinoside prodrug YNK-01 in rat liver. Biochem. Pharmacol. 1990;39:1505–1512
  18. Tatsumi N, Yamada K, Ohshima T, Nakamura T, Ohno R, Masaoka T, et al.  Phase II study of YNK01 (1-beta-d-arabinofuranosylcytosine-5′-stearylphosphate) on hematological malignancies. Gan. To. Kagaku. Ryoho. 1990;17:2387–2395
  19. Fukuoka M, Miyazaki T, Yoshida Y, Hattori M, Niitani H, Nakamura T, et al.  Phase 1 study of YNK01 (1-beta-d-arabinofuranosylcytosine 5′-stearylphosphate). Gan. To. Kagaku. Ryoho. 1990;17:2213–2219
  20. Braess J, Freund M, Hanauske A, Heil G, Kaufmann C, Kern W, et al.  Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma-phase I/II studies and pharmacokinetics. Leukemia. 1998;12:1618–1626
  21. Guilhot F, Harousseau JL, Fiere D, Rapp MJ, Michallet M, David M, et al.  Phase IIII trial of ara-C prodrug YNK01 in chronic myelogenous leukemia patients: hematologic and cytogenetic responses. Proc. ASCO. 1996;15:449
  22. Guilhot F, Maloisel F, Guyotat D, Ifrah N, Michallet M, Reiffers J, et al.  A phase II study to assess efficacy and safety of interferon a 2b (IFN) in combination with oral cytarabine ocfosfate (YNK01) in patients with chronic myelogenous leukemia (CML). Blood. 1998;92(Suppl. 1):627a
  23. Talpaz M, Kantarjian HM, McDredie KB, Trujillo J, Keating MJ, Gutterman JU. Hematologic response and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. New Engl. J. Med. 1986;314:1065–1069
  24. Mühlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G, et al.  Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myelogenous leukemia (CML) during interferon treatment. A new strategy for remission assessment. Gene Chrom. Cancer. 1998;21:90–100
  25. Duba HQ, Peter S, Hilbe W, Fluckinger T, Fridrik M, Erdel M, et al.  Monitoring of remission status by fluorescence in situ hybridisation (FISH) in chronic myelogenous leukemia patients treated with interferon α. Int. J. Oncol. 1999;14:145–150

PII: S0145-2126(00)00036-9

Leukemia Research
Volume 24, Issue 7 , Pages 583-587 , July 2000

Article Tools

* Image Usage & Resolution